Market's view on Lunglife Ai
Published on April 2024
- The company’s CEO presented a compelling roadmap for commercialisation over the next 12 months, suggesting it’s an opportunity worth monitoring.
- Stock watchers have observed buyers returning to the market after a period of decline.
- Concerns have been raised about the company’s request for the authority to issue up to 100 million shares, significantly more than the current 25 million, which has been perceived as a potential red flag.
- Doubts were expressed regarding the commitment of the directors, noting minimal purchasing by them during a share placing.
- The market was suspected of anticipating an announcement prior to a recent fundraising event.
- The company managed a fundraising of £1.8 million at a 15.7% discount, which is intended to fund operations until April 2025, with hopes for a market recovery by then.
- Questions were raised about the necessity for a new fundraising in the near future.